| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30018545 | HIV | ENSG00000086205.18 | protein_coding | FOLH1 | Yes | No | 2346 | Q04609 |
| TVIS20065535 | HPV | ENSG00000086205.18 | protein_coding | FOLH1 | Yes | No | 2346 | Q04609 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FOLH1 |
|---|---|
| DrugBank ID | DB00142 |
| Drug Name | Glutamic acid |
| Target ID | BE0000568 |
| UniProt ID | Q04609 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 11916141; 15837926; 15336276 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Rodriguez CE, Lu H, Martinez AR, Hu Y, Brunelle A, Berkman CE: Inhibition of glutamate carboxypeptidase II by phosphonamidothionate derivatives of glutamic acid. J Enzyme Inhib. 2001 Oct;16(4):359-65.@@Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ: Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5981-6. Epub 2005 Apr 18.@@Maung J, Mallari JP, Girtsman TA, Wu LY, Rowley JA, Santiago NM, Brunelle AN, Berkman CE: Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem. 2004 Sep 15;12(18):4969-79. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | N[C@@H](CCC(O)=O)C(O)=O |
| Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
| PharmGKB | PA449776 |
| ChEMBL | CHEMBL575060 |
